Cannara Biotech Inc.
LOVFF
$1.34
-$0.02-1.47%
OTC PK
05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
---|---|---|---|---|---|
Revenue | 35.70% | 26.34% | 27.49% | 23.90% | 22.42% |
Total Other Revenue | -- | -- | -- | 66.78% | -28.19% |
Total Revenue | 35.70% | 26.34% | 27.49% | 24.72% | 21.68% |
Cost of Revenue | 11.27% | -11.63% | 31.40% | 45.21% | 70.69% |
Gross Profit | 80.35% | 169.61% | 22.12% | 6.61% | -20.19% |
SG&A Expenses | 14.19% | -4.91% | 30.68% | 40.55% | 27.56% |
Depreciation & Amortization | -9.57% | 16.66% | -31.90% | 280.44% | -8.59% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 10.57% | -10.17% | 28.94% | 44.62% | 54.04% |
Operating Income | 349.19% | 372.44% | 20.65% | -19.29% | -66.39% |
Income Before Tax | 177.46% | 228.82% | 42.89% | -20.16% | -31.21% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 98.41% | 190.28% | 8.60% | 20.91% | -31.21% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 98.41% | 190.28% | 8.60% | 20.91% | -31.21% |
EBIT | 349.19% | 372.44% | 20.65% | -19.29% | -66.39% |
EBITDA | 164.79% | 1,268.20% | 12.41% | -10.41% | -47.88% |
EPS Basic | 95.15% | 189.82% | 8.77% | 24.53% | -30.67% |
Normalized Basic EPS | 28,300.00% | 227.93% | 42.99% | -21.82% | -100.67% |
EPS Diluted | 93.20% | 185.91% | 27.40% | 20.00% | -33.48% |
Normalized Diluted EPS | 27,900.00% | 225.70% | 42.45% | -23.18% | -100.68% |
Average Basic Shares Outstanding | 1.57% | 0.60% | -0.22% | -2.83% | -0.72% |
Average Diluted Shares Outstanding | 1.18% | 2.48% | 0.62% | -1.20% | 0.13% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |